SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fermenta Biotech - Quaterly Results

14 Feb 2022 Evaluate
The revenue for the December 2021 quarter is pegged at Rs. 854.08 millions against Rs. 876.70 millions recorded during the year-ago period.The company suffered a huge decline of -83.57% to Rs. 18.16  millions from Rs. 110.50 millions  of corresponding previous quarter.Operating profit for the quarter ended December 2021 decreased to 134.04 millions as compared to 238.14 millions of corresponding quarter ended December 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 854.08 876.70 -2.58 2933.02 2819.18 4.04 3728.22 3005.07 24.06
Other Income 11.32 6.61 71.26 45.56 28.75 58.47 66.18 123.13 -46.25
PBIDT 134.04 238.14 -43.71 619.44 785.31 -21.12 1003.36 818.05 22.65
Interest 41.25 39.63 4.09 127.49 130.56 -2.35 180.75 193.20 -6.44
PBDT 92.79 198.51 -53.26 491.95 654.75 -24.86 822.61 624.85 31.65
Depreciation 62.10 46.73 32.89 176.47 130.89 34.82 190.31 149.38 27.40
PBT 30.69 151.78 -79.78 315.48 523.86 -39.78 632.30 475.47 32.98
TAX 12.53 41.28 -69.65 103.80 100.85 2.93 112.60 -161.24 -169.83
Deferred Tax 7.13 14.49 -50.79 48.67 7.10 585.49 0.03 -194.89 -100.02
PAT 18.16 110.50 -83.57 211.68 423.01 -49.96 519.70 636.71 -18.38
Equity 144.24 144.24 0.00 144.24 144.24 0.00 144.24 144.24 0.00
PBIDTM(%) 15.69 27.16 -42.22 21.12 27.86 -24.18 26.91 27.22 -1.14

Fermenta Biotech Share Price

312.55 -9.30 (-2.89%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×